Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study

Scardino, 2005, Update: NCCN prostate cancer clinical practice guidelines, JNCCN, 3, S29

Loblaw, 2007, Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline, J Clin Oncol, 25, 1596, 10.1200/JCO.2006.10.1949

Glehen, 2004, Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia, Lancet Oncol, 5, 219, 10.1016/S1470-2045(04)01425-1

Bristow, 2002, Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis, J Clin Oncol, 20, 1248, 10.1200/JCO.20.5.1248

1998, Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group, Lancet, 352, 930, 10.1016/S0140-6736(98)03301-7

Flanigan, 2001, Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer, N Engl J Med, 345, 1655, 10.1056/NEJMoa003013

Mickisch, 2001, Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial, Lancet, 358, 966, 10.1016/S0140-6736(01)06103-7

Nitta, 1995, Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas, Cancer, 75, 2727, 10.1002/1097-0142(19950601)75:11<2727::AID-CNCR2820751115>3.0.CO;2-H

Temple, 2004, Use of surgery among elderly patients with stage IV colorectal cancer, J Clin Oncol, 22, 3475, 10.1200/JCO.2004.10.218

Harlan, 2003, The surveillance, epidemiology, and end-results program database as a resource for conducting descriptive epidemiologic and clinical studies, J Clin Oncol, 21, 2232, 10.1200/JCO.2003.94.023

Greene, 2002

Fine, 1999, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, 94, 496, 10.1080/01621459.1999.10474144

Humphreys, 2013, Impact of age at diagnosis on outcomes in men with castrate-resistant prostate cancer (CRPC), J Cancer, 4, 304, 10.7150/jca.4192

Scosyrev, 2012, Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality, Cancer, 118, 3062, 10.1002/cncr.26392

Bertaglia, 2013, Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer, Clin Genitourin Cancer, 11, 325, 10.1016/j.clgc.2013.01.002

Ryan, 2006, Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from PCaSURE, Urol Oncol, 24, 396, 10.1016/j.urolonc.2005.09.003

Small, 2006, Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer, J Clin Oncol, 24, 3089, 10.1200/JCO.2005.04.5252

de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618

de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X

Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506

2013

Steuber, 2011, Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study, BJU Int, 107, 1755, 10.1111/j.1464-410X.2010.09730.x

Ghavamian, 1999, Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison, J Urol, 161, 1223, 10.1016/S0022-5347(01)61640-9

Engel, 2010, Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer, Eur Urol, 57, 754, 10.1016/j.eururo.2009.12.034

Swanson, 2004, Failure after primary radiation or surgery for prostate cancer: differences in response to androgen ablation, J Urol, 172, 525, 10.1097/01.ju.0000132412.74468.57

Thompson, 2002, Impact of previous local treatment of prostate cancer on subsequent metastatic disease, J Urol, 168, 1008, 10.1016/S0022-5347(05)64562-4

Kantoff, 2010, Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N Engl J Med, 363, 411, 10.1056/NEJMoa1001294

Comen, 2011, Clinical implications of cancer self-seeding, Nat Rev Clin Oncol, 8, 369, 10.1038/nrclinonc.2011.64

Resel Folkersma, 2012, Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer, Urology, 80, 1328, 10.1016/j.urology.2012.09.001

Warde, 2011, Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial, Lancet, 378, 2104, 10.1016/S0140-6736(11)61095-7